These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 12682712)

  • 1. Motor delays in MDMA (ecstasy) exposed infants persist to 2 years.
    Singer LT; Moore DG; Min MO; Goodwin J; Turner JJ; Fulton S; Parrott AC
    Neurotoxicol Teratol; 2016; 54():22-8. PubMed ID: 26806601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Common side effects of MDMA-assisted psychotherapy.
    Murray CH
    Neuropsychopharmacology; 2024 Jul; 49(8):1206-1207. PubMed ID: 38740900
    [No Abstract]   [Full Text] [Related]  

  • 3. [Synthetic drugs: from use to multiple consumption. Some associated risks and a proposal for therapeutic intervention].
    Royo-Isach J; Magrané M; Blancafort F; Ferrer J
    Aten Primaria; 2004 Mar; 33(4):209-13. PubMed ID: 15023325
    [No Abstract]   [Full Text] [Related]  

  • 4. MDMA administration during adolescence exacerbates MPTP-induced cognitive impairment and neuroinflammation in the hippocampus and prefrontal cortex.
    Costa G; Simola N; Morelli M
    Psychopharmacology (Berl); 2014 Oct; 231(20):4007-18. PubMed ID: 24687411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Editorial note: MDMA-induced dopamine neurotoxicity.
    Warburton DM
    Psychopharmacology (Berl); 2004 Jan; 171(2):228. PubMed ID: 14634718
    [No Abstract]   [Full Text] [Related]  

  • 6. Parkinson's disorder, psychomotor problems and dopaminergic neurotoxicity in recreational ecstasy/MDMA users.
    Parrott AC; Buchanan T; Heffernan TM; Scholey A; Ling J; Rodgers J
    Psychopharmacology (Berl); 2003 Jun; 167(4):449-50. PubMed ID: 12682712
    [No Abstract]   [Full Text] [Related]  

  • 7. Response to: Parrott AC, Buchanan T, Heffernan TM, Scholey A, Ling J, Rodgers J (2003) Parkinson's disorder, psychomotor problems and dopaminergic neurotoxicity in recreational ecstasy/MDMA users. Psychopharmacology 167(4):449-450.
    Sumnall HR; Jerome L; Doblin R; Mithoefer MC
    Psychopharmacology (Berl); 2004 Jan; 171(2):229-30. PubMed ID: 14634709
    [No Abstract]   [Full Text] [Related]  

  • 8. The reality of psychomotor problems, and the possibility of Parkinson's disorder, in some recreational ecstasy/MDMA users: a rejoinder to Sumnall et al. (2003).
    Parrott AC; Rodgers J; Buchanan T; Scholey AB; Heffernan T; Ling J
    Psychopharmacology (Berl); 2004 Jan; 171(2):231-3. PubMed ID: 14634710
    [No Abstract]   [Full Text] [Related]  

  • 9. Cognitive deficits and cognitive normality in recreational cannabis and Ecstasy/MDMA users.
    Parrott A
    Hum Psychopharmacol; 2003 Mar; 18(2):89-90. PubMed ID: 12590401
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacological aspects of the combined use of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and gamma-hydroxybutyric acid (GHB): a review of the literature.
    Uys JD; Niesink RJ
    Drug Alcohol Rev; 2005 Jul; 24(4):359-68. PubMed ID: 16234132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of the mechanisms involved in the acute MDMA (ecstasy)-induced hyperthermic response.
    Green AR; O'shea E; Colado MI
    Eur J Pharmacol; 2004 Oct; 500(1-3):3-13. PubMed ID: 15464016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased intensity of Ecstasy and polydrug usage in the more experienced recreational Ecstasy/MDMA users: a WWW study.
    Scholey AB; Parrott AC; Buchanan T; Heffernan TM; Ling J; Rodgers J
    Addict Behav; 2004 Jun; 29(4):743-52. PubMed ID: 15135556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ecstasy/MDMA attributed problems reported by novice, moderate and heavy recreational users.
    Parrott AC; Buchanan T; Scholey AB; Heffernan T; Ling J; Rodgers J
    Hum Psychopharmacol; 2002 Aug; 17(6):309-12. PubMed ID: 12404677
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.